drugset / Trial / NCT00940342
Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if giving granulocyte-macrophage colony-stimulating factor (GM-CSF) together with rituximab can improve the ability of rituximab to shrink or slow the growth of Chronic Lymphocytic Leukemia (CLL). The safety of this combination treatment will also be studied.
Timeline
- Start
- 2004-10-12
- Primary completion
- 2017-01-05
- Completion
- 2017-01-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GM-CSF | Protein / enzyme biologic | 250 ug | Subcutaneous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |